Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term leukemia. Found 21 abstracts

no pagination
Prabhu VV, Talekar MK, Lulla AR, Kline CL, Zhou L, Hall J, Van den Heuvel AP, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell cycle (Georgetown, Tex). 2018 Feb 19;17(4):468-78.   PMCID: PMC5927637
Isoda T, Moore AJ, He Z, Chandra V, Aida M, Denholtz M, Piet van Hamburg J, Fisch KM, Chang AN, Fahl SP, Wiest DL, Murre C. Non-coding Transcription Instructs Chromatin Folding and Compartmentalization to Dictate Enhancer-Promoter Communication and T Cell Fate. Cell. 2017 Sep 21;171(1):103-119e18.   PMCID: PMC5621651
Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA, Infante JR. Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clinical Cancer Research. 2012 Sep;18(17):4775-84.   PMCID: Private funding
Kadariya Y, Tang BQ, Myers CB, Fukui J, Peterson JR, Kruger WD. Chemical Genetic Screening for Compounds That Preferentially Inhibit Growth of Methylthioadenosine Phosphorylase (MTAP)-Deficient Saccharomyces cerevisiae. Journal of Biomolecular Screening. 2011 Jan;16(1):44-52.   PMCID: PMC3019245
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES. Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. 2011 Mar;9(3):280-317.   PMCID: not NIH funded
Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, Jette CA, Testa JR, Neuberg DS, Langenau DM, Kutok JL, Zon LI, Traver D, Fleming MD, Kanki JP, Look AT. T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer cell. 2010 Oct;18(4):353-66.   PMCID: PMCID: PMC3003429 [Available on 2011/10/1]
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. Clinical Cancer Research. 2009 Sep;15(18):5910-6.   PMCID: PMC2861356
O'Brien S, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Radich JP, Shah NP, Smith BD, Snyder DS, Talpaz M, Wetzler M. Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 2009 Oct;7(9):984-1023.   PMCID: not NIH funded
Greer BE, Bundy BN, Ozols RF, Fowler JA, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study. Gynecologic Oncology. 2005 Oct;99(1):71-9.
Nowell P, Rowley J, Knudson A. Cancer genetics, cytogenetics - defining the enemy within. Nature medicine. 1998 Oct;4(10):1107-11.
Das IJ, Cheng CW, Fein DA, Coia LR, Curran WJ, Fowble B. Dose estimation to critical organs from vertex field treatment of brain tumors. International Journal of Radiation Oncology Biology Physics. 1997 Mar 15;37(5):1023-9.
Morgan AS, Ciaccio PJ, Tew KD, Kauvar LN. Isozyme specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemotherapy and Pharmacology. 1996 Feb;37(4):363-70.
Mysliwiec T, Perego R, Kruh GD. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain. Oncogene. 1996 Feb;12(3):631-40.
Smith MR. Non-Hodgkin's lymphoma. Current Problems in Cancer. 1996 Jan;20(1):6-77.
Wang BL, Mysliwiec T, Feller SM, Knudsen B, Hanafusa H, Kruh GD. Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk. Oncogene. 1996 Oct 03;13(7):1379-85.
Kruh GD, Gaughan KT, Godwin A, Chan A. Expression Pattern of Mrp in Human Tissues and Adult Solid Tumor-Cell Lines. Journal of the National Cancer Institute. 1995 Aug 16;87(16):1256-8.
Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, Alkatib A. Antisense Oligodeoxyribonucleotide Down-Regulation of Bcl-2 Gene-Expression Inhibits Growth of the Low-Grade Non-Hodgkins- Lymphoma Cell-Line Wsu-Fsccl. Cancer Gene Therapy. 1995 Sep;2(3):207-12.
Burch JB, Davis DL. Alternative Promoter Usage and Splicing Options Result in the Differential Expression of Messenger-Rnas Encoding 4 Isoforms of Chicken Vbp, a Member of the Par Subfamily of Bzip Transcription Factors. Nucleic acids research. 1994 Nov 11;22(22):4733-41.
Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA. Expression Complementary-DNA Library Transfer Establishes Mrp as a Multidrug-Resistance Gene. Cancer Research. 1994 Apr;54(7):1649-52.
Gilks CB, Ho VC, Gascoyne RD, Ellison DJ. T-Cell Receptor Variable Region Gene-Expression in Cutaneous T- Cell Lymphomas. Journal of Cutaneous Pathology. 1992 Feb;19(1):21-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term leukemia

leukemia gene cells therapy p-glycoprotein chronic myelogenous cancer survival cell-lines product cloning chemotherapy tyrosine kinase lymphoma binding transplantation breast-cancer sezary syndrome cell-line vertex field bcl-2 proliferation gonadal dose 1st complete remission activator protein a kinase retinoblastoma irradiation trans-retinoic acid biology mechanisms mtap genes potentiate risk myelodysplastic syndrome burkitt-lymphoma p-glycoprotein expression yeast mln8054 chronic lymphocytic- mitomycin-c donor lymphocyte infusions death Abl chimera chemotherapeutic agents specificity single-loop domain 2nd gene-expression bone-marrow transplantation ethacrynic-acid gene- Abl imipridone histiocytic lymphoma hl60 cells low-grade lymphoma melphalan mdr1 cytogenetics term follow-up oncogenic activation risk trials loop extrusion sh3 domain multidrug transporter target bladder-cancer oligodeoxyribonucleotides apoptosis c-abl acute myeloid stem-cell transplantation common cdna cloning antisense advanced stage ovarian cancer second-look laparotomy GST inhibitor homozygous deletions acute promyelocytic leukemia transgenic zebrafish myristoylation murine leukemia-virus Arg c-myc deletion brain tumors southwest-oncology-group treatment messenger-rna NCCN Guidelines younger adults ornithine-decarboxylase transporter cdkn2 mesylate cell-cycle src homology-3 domain childhood aneuploidy allogenic HSCT NCCN Clinical Practice Guidelines amn107 epstein-barr-virus polymerase-chain-reaction large-cell lymphoma lymphocytes response radiation-therapy Onc201 identification system codeletion compartmentalization stem-cell sunitinib kit mutations complete cytogenetic phase separation translocation resistance acute myelogenous mycosis-fungoides children dosimetry skin-cancer monoethyl ester sphingosine 1-phosphate selective inhibitor 18) chronic myeloid-leukemia diffuse t(14 drug screening methionine salvage pathway-yeast-genetic-chemical interaction arsenic trioxide transforming activity cohesin small-molecule inhibitor nilotinib acquired-resistance photon beams karyotyping imatinib mesylate leukemia treatment in older patients c-myc protein binding protein drug sensitivity oligodeoxynucleotides follicular non-hodgkins lymphoma
Last updated on Friday, January 03, 2020